250 boston post road, LLC

attn: steven brauser
100 west 18th street, cf1
new york, new york 10011

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 03, 2014

NYS DOS ID#
4508148

County
WESTCHESTER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - 250 BOSTON POST ROAD, LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Recalling Spygate wreckage, the original NY-Boston scandal
    By Mark Cannizzaro - Wednesday Sep 6, 2017

    Ten years ago “Spygate’’ consumed the NFL with a news cycle it wished never got started. It wrecked relationships, cost the Patriots draft picks and money, and forever tarnished the reputation of the franchise and its Hall of Fame-bound head coach, Bill Belichick. Eric Mangini, then the Jets coach, blew the whistle on the Patriots...

    Source: New York Post: Sports
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Mets 2018 schedule: Fenway trip and more Subway Series games
    By Mike Puma - Tuesday Sep 12, 2017

    The Mets’ appearance at Fenway Park for the first time since 2009 is among the novelties of the team’s schedule for next season, which was released Tuesday. But facing the Red Sox in Boston will have to wait until Sept. 14-16, as part of the Mets’ final road trip of the season. Facing the AL...

    Source: New York Post: Sports
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York